<DOC>
	<DOC>NCT00747175</DOC>
	<brief_summary>The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes</brief_summary>
	<brief_title>A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male or surgically sterile female of nonchildbearing potential (postmenopausal, ie natural or induced menopause with last menstruation &gt;1 year ago and LH and FSH in the postmenopausal range, and/or have undergone hysterectomy and/or bilateral oophorectomy Diagnosed diabetes Mellitus patients treated with diet and exercise alone or with up to two oral antidiabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment HbA1c â‰¤10.5 % at screening (HbA1c value according to international DCCT standard) Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP History ischemic heart disease, stroke, transitorisk ischemic attack or symptomatic peripheral vascular disease Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results. Positive test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to Hepatitis C virus</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Type 2 diabetes</keyword>
</DOC>